Combination of an IRS / STAT3 dual modifier and an anticancer agent for the treatment of cancer

摘要

The present invention provides: (i) a modulator of a protein kinase (PK) selected from epidermal growth factor inhibitors (EGFR inhibitors) and EGFR antibodies; (ii) inhibitors of mammalian rapamycin target protein (mTOR); (iii) Mitogen-activated protein kinase (MEK) inhibitors; (iv) mutant B-Raf inhibitors; (v) chemotherapeutic agents such as gemcitabine, 5-FU, irinotecan and oxaliplatin; and (vi) certain of them The present invention relates to the treatment of cancer using a combination therapy comprising a dual modifier of insulin receptor substrate (IRS) and signal transduction transcription factor 3 (Stat3) in combination. The combination is used to treat tumors that develop resistance to EGFR inhibitors, EGFR antibodies, mTOR inhibitors, MEK inhibitors, mutant B-Raf inhibitors, chemotherapeutic agents, and certain combinations thereof Alternatively, tumor acquired resistance to any of the inhibitors or drugs can be prevented, or tumor recurrence after discontinuation of treatment with any of the inhibitors or drugs or combinations thereof can be prevented. The combination provides at least an additive and preferably synergistic therapeutic effect. The invention further relates to the treatment of cancer using a combination therapy comprising a dual modulator of IRS and Stat3 in combination with an immunotherapeutic agent. The combination can be used to sensitize a tumor to immunotherapy. [Selection figure] None